Utrecht, the Netherlands, and Cambridge, Massachusetts-based Gilde Healthcare closed Gilde Healthcare V, a €416m ($450m) venture and growth capital fund.
Gilde Healthcare V is backed by a balanced mix of international investors including banks, pension funds, fund-of-funds, sovereign funds, endowments, family offices, entrepreneurs and Gilde partners. Disclosed investors include longstanding corporate partner Royal Philips and Rabo Corporate Investments from The Netherlands, HANIEL and KfW Capital from Germany, BNP Paribas Fortis Private Equity and Belgian Growth Fund from Belgium, Danish Growth Fund from Denmark and the European Investment Fund (EIF) from Luxembourg.
The new fund targets growth opportunities in a broad range of healthcare sectors including digital health, medtech and therapeutics both in Europe and North America. It will typically make equity investments in a single portfolio company of between €10-40m.
Led by Pieter van der Meer, Managing Partner, Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity.
The firm recently exited infectious disease (including COVID-19) diagnostic platform STAT-Dx to Qiagen, the trade sale of Breath Therapeutics (treatment of lung transplant rejection) to Zambon Pharma and the NASDAQ listing of Axonics, focused on the treatment of overactive bladder. Gilde Healthcare also has a strong track record with healthcare unicorns such as Ablynx, Ascendis Pharma and uniQure.